Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Promising results from RNA vaccine in melanoma
August 2017
SHARING OPTIONS:

MAINZ, Germany—July saw biotechnology company BioNTech AG share Phase 1 trial results for IVAC MUTANOME, an individualized RNA vaccine based on patient-specific mutations. The vaccine was found to induce strong immunogenicity and antitumor activity in high-risk, late-stage melanoma patients. In addition, most patients demonstrated extended progression-free survival compared to historical controls. The vaccine boosted immunity against several tumor antigens in all patients, and eight were still tumor-free at 23 months, though five had tumor relapses before beginning neo-epitope vaccination. Two of those saw objective responses after neo-epitope vaccination, and one had a complete response after vaccination and anti-PD-1 therapy.
 
“Each patient developed immune responses against multiple vaccine targets. This suggests that in principle, it may be possible to train a patient’s immune system to help fight their cancer across a wide array of tumor types,” said Ugur Sahin, Founder and CEO of BioNTech.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.